Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Hofseth BioCare ASA – Resolution to increase the share capital

HBCRegulatory press release2026-11-05 18:32

Reference is made to the stock exchange announcements from Hofseth BioCare ASA ("HBC" or the "Company") published on 30 June 2026 regarding the resolution passed at the annual general meeting that remuneration payable to the board of directors of the Company (the "Board") for 2026 shall be paid through the issuance of ordinary shares to Board members. The general meeting further resolved to grant the Board authorisation to increase the share capital in the Company through the issuance of new shares with a total value of up to NOK 1,550,000, corresponding to 155,000,000 shares, each with a par value of NOK 0.01 (the "Board Authorisation").

Pursuant to the Board Authorisation, the Board resolved at a Board meeting held today, on 5 November 2026, to increase the share capital by NOK 2,375 through the issuance of 237,500 shares allocated to the members of the Board as remuneration for the first half of 2026.

Following registration of the capital increase in the Norwegian Register of Business Enterprises, the share capital of the Company will be NOK 5,224,731.38, divided into 506,473,138 ordinary shares and 16,000,000 unlisted preference shares in Class B, in each case with a par value of NOK 0.01.

This disclosure is subject to the disclosure requirement pursuant to section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jon Olav Ødegård, CEO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no